About Monocarboxylate transporter 2
Monocarboxylate transporter 2 (SLC16A7) is a protein
from Homo sapiens identified by UniProt accession
O60669, 478 residues long.
MolForge cross-references it against 0 known binders and
136 disease associations.
Target properties
| Protein name | Monocarboxylate transporter 2 |
| UniProt accession | O60669 |
| Gene | SLC16A7 |
| Organism | Homo sapiens |
| Length | 478 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (136)
Diseases linked to this target (Open Targets).
- body height · score 0.43
- BMI-adjusted waist-hip ratio · score 0.36
- self reported educational attainment · score 0.34
- mean corpuscular volume · score 0.33
- BMI-adjusted hip circumference · score 0.30
- diet measurement · score 0.29
- mathematical ability · score 0.28
- neurodegenerative disease · score 0.28
- multiple sclerosis · score 0.28
- lysosomal storage disease · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60669-F1 | alphafold | PREDICTED | 84.46 | — |
Amino-acid sequence (478 residues)
MPPMPSAPPV HPPPDGGWGW IVVGAAFISI GFSYAFPKAV TVFFKEIQQI FHTTYSEIAW ISSIMLAVMY AGGPVSSVLV NKYGSRPVVI AGGLLCCLGM VLASFSSSVV QLYLTMGFIT GLGLAFNLQP ALTIIGKYFY RKRPMANGLA MAGSPVFLSS LAPFNQYLFN TFGWKGSFLI LGSLLLNACV AGSLMRPLGP NQTTSKSKNK TGKTEDDSSP KKIKTKKSTW EKVNKYLDFS LFKHRGFLIY LSGNVIMFLG FFAPIIFLAP YAKDQGIDEY SAAFLLSVMA FVDMFARPSV GLIANSKYIR PRIQYFFSFA IMFNGVCHLL CPLAQDYTSL VLYAVFFGLG FGSVSSVLFE TLMDLVGAPR FSSAVGLVTI VECGPVLLGP PLAGKLVDLT GEYKYMYMSC GAIVVAASVW LLIGNAINYR LLAKERKEEN ARQKTRESEP LSKSKHSEDV NVKVSNAQSV TSERETNI
Explore Monocarboxylate transporter 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets